Prognostic and predictive potential molecular biomarkers in colon cancer

Chirurgia (Romania)

Volumn 108, Issue 2, 2011, Pages 177-185

  Nastase, A ^a   Paslaru L ^b   Niculescu, A M ^a   Ionescu, M ^c   Dumitraaecu T ^c   Herlea, V ^c   Dima, S ^c   Gheorghe, C ^c   Lazar, V ^d   Popescu, I ^c  

^a Molecular Biology and Biobanking Laboratory   (Romania)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c FUNDENI CLINICAL INSTITUTE   (Romania)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Biomarkers; Colon cancer; QPCR

Indexed keywords

DEFICIENS PROTEIN; INTERLEUKIN 8; MATRILYSIN; MESSENGER RNA; MMP7 PROTEIN, HUMAN; OSTEOPONTIN; SPP1 PROTEIN, HUMAN; TUMOR MARKER;

AGED; ARTICLE; CANCER STAGING; CELL TRANSFORMATION; CHEMISTRY; COLON TUMOR; DISEASE COURSE; EARLY DIAGNOSIS; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

AGED; CELL TRANSFORMATION, NEOPLASTIC; COLONIC NEOPLASMS; DEFICIENS PROTEIN; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-8; MALE; MATRIX METALLOPROTEINASE 7; MIDDLE AGED; NEOPLASM STAGING; OSTEOPONTIN; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84874072567     PISSN: 12219118     EISSN: 1842368X     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Half E, Arber N. Colon cancer: preventive agents and the present status of chemoprevention. Expert Opin Pharmacother. 2009;10(2):211-9.
2. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759-67.
3. Nicola V, Croce C M, Muller F. Pathogenetic and Clinical Relevance of MicroRNAs in Colorectal Cancer. Cancer Genomics and Proteomics. 2009;6(4):195-204.
4. Tejpar S, Bertagnolli M, Bosman F, Lenz Heinz J, Garraway L, Waldmanf F, et al. Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery. The Oncologist. 2010;15(4):390-404, doi:10.1634/ theoncologist.2009- 0233
5. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319(9):525-32.
6. Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, Nakamura Y, et al. Allelotype of colorectal carcinomas. Science. 1989;244(4901):207-11. (Pubitemid 19110299)
7. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998;396(6712):643-9. (Pubitemid 29003936)
8. Lothe RA, Peltomäki P, Meling GI, Aaltonen LA, Nyström- Lahti M, Pylkkänen L, et al. Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. 1993;53(24):5849-52. (Pubitemid 24006146)
9. Grady WM. Genomic instability and colon cancer. Cancer Metastasis Rev. 2004;23:11-27. (Pubitemid 38221594)
10. Aaltonen LA, Peltomäki P, Leach FS et al. Clues to the pathogenesis of familial colorectal cancer. Science. 1993;260: 812-6. (Pubitemid 23167611)
11. Ionov Y, Peinado MA, Malkhosyan S et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature. 1993;363:558-561. (Pubitemid 23186645)
12. Mates IN, Csiki I, Mates D, Constantinescu V, Badea P, Dinu D, et al. Association of common genetic variants with colorectal cancer risk in a Romanian sample. Chirurgia (Bucur). 2010; 105(6):749-57.
13. Osian G, Procopciuc L, Vlad L, Mocan T, Cristea PG. Correlation between C677T and A1298C mutations of the MTHFR gene and therapeutic prognostic elements in colorectal cancer. Chirurgia (Bucur). 2010;105(3):373-8. [Article in Romanian]
14. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. JR K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757-65.
15. Ferté C, André F, Soria JC. Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. Nat Rev Clin Oncol. 2010;7(7):367-80. Epub 2010 Jun 15.
16. Yoon SO, Park SJ, Yun CH, Chung AS. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol. 2003;36(1):128-37.
17. Remy L, Trespeuch C, Bachy S, Scoazec JY, Rousselle P. Matrilysin 1 influences colon carcinoma cell migration by cleavage of the laminin-5 beta3 chain. Cancer Res. 2006; 66(23):11228-37. (Pubitemid 46009951)
18. Hideaki Nagase, Robert Visse, Gillian Murphy. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69(3):562-73. (Pubitemid 43139720)
19. Kurokawa S, Arimura Y, Yamamoto H, Adachi Y, Endo T, Sato T, et al. Tumour matrilysin expression predicts metastatic potential of stage I (pT1) colon and rectal cancers. Gut. 2005; 54(12):1751-8. (Pubitemid 41697675)
20. Wai Py, Kuo PC. The role of Osteopontin in tumor metastasis J Surg Res. 2004;121:228-241. (Pubitemid 39387464)
21. Yeatman TJ, Chambers AF. Osteopontin and colon cancer progression. Clin Exp Metastasis. 2003;20(1):85-90. (Pubitemid 36308140)
22. Agrawal D, Chen T, Irby R, Quachenbush J, Chambers AF, Szabo M, et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst. 2002;94:513-521. (Pubitemid 34411290)
23. Rohde F, J Rimkus C, Friederichs J, Rosemberg R, Marthen C Doll, et al. Expression of osteopontin, a target gene of deregulated Wnt signaling, predicts survival in colon cancer Int J C Cancer. 2007;121(8):1717-23. (Pubitemid 47417288)
24. Agnihotri R, Crawford HC, Haro H, Matrisian LM, Havrda MC, Liaw L. Osteopontin, a novel substrate for matrix metalloproteinase- 3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol Chem. 2001;276(30):28261-7. Epub 2001
25. Yang SK, Eckmann L, Panja A, Kagnoff MF. Differential and regulated expression of C-X-C, C-C, and C-chemokines by human colon epithelial cells. Gastroenterology. 1997;113(4): 1214-23. (Pubitemid 27418975)
26. Wang JM, Deng X, W Gomg, Chemokines and their role in tumor growth and metastasis. J Immunol Methods. 1998; 220(1-2):1-17. (Pubitemid 28527062)
27. Li A, Dubey S, Varney et al. IL8 directly enhanced endothelial cell survival, proliferation and matrix metalloproteinases production and regulates angiogenesis. J Immunol. 2003;170: 3369-3376. (Pubitemid 36302216)
28. Rubie C, Frick VO, Pfeil S,Wagner M, Kollmar O, Kopp B, et al. Correlation of IL-8 induction, progression and metastatic potential colorectal cancer. World Gastroenterol. 2007;13(37) :4996-5002 (Pubitemid 47496833)
29. Shi Q, Abbruzzess JL, Huang S, Fidler IJ, Xiong Q, Xie K. Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res. 1999;5(11):3711-21.
30. Varney ML, Johansson SL, Singh RK. Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma. Am J Clin Pathol. 2006 Feb;125(2):209-16. (Pubitemid 43167161)
31. Li A, Varney ML, Singh RK. Expression of IL-8 and its receptors in human colon carcinoma cells with different metastatic potentials. Clin Cancer Res. 2001;7:3298-3304. (Pubitemid 32963857)
32. Li A, Varney ML, Valasek J, Godfrey M, Dave BJ, Singh RK. Autocrine role of IL-8 in induction of endothelial cells proliferation, survival, migration and MMP2 production and angiogenesis. Angiogenesis. 2005;8:63-71. (Pubitemid 41223840)
33. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth factor Rev. 2001;12:375-391. (Pubitemid 32851749)
34. Itoh Y, Joh T, Tanida S, Sasaki M, Kataoka H Oshima, Ogasawara N, et al. Il-8 promotes cell proliferation and migration through metalloproteinase- cleavage pro-HB-EGF in in human colon carcinoma cells. Cytokine. 2005;29(6):275-82. (Pubitemid 40320928)
35. Terzić J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology. 2010;138(6):2101-2114.e5
36. Dhawan P and Richmond A, Role of CXCL1 in tumorigenesis of melanoma, J leukoc Biol. 2002; 72(1):9-18
37. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvment of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50-56. (Pubitemid 32225831)
38. Wang D, Sai J, Carter G, Sachpatzidis A, Lolis E, Richmond A. PAK1 Kinase is required for CXCL1-induced chemotaxis. Biochemistry. 2002;41(22):7100-7107. (Pubitemid 34575683)
39. Wang D, Wang H, Brown J, Daikoku T, Ning W, Shi Q, et al. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer, JEM (J. Exp Med). 2006;203(4):941-51.
40. Bandapalli OR, Goepinger SM, Gaida M, Wente M, Schirmacher P, Brand K. Down-regulation of CXCL1 inhibits growth of colorectal liver metastasis. Cytokine. 2008; 43(3):325.
41. Le Clair RJ, Durmus T, Wang Q, Pyagay P, Trezic A, Lindler V. Cthrc1 is a novel inhibitor of Tumor Necrosis Factor-beta signaling and neointimal lesion formation, Circ Res 2007; 100(6):826-33. (Pubitemid 46555687)
42. Tang L, Dai DL, Mingwan S, Martinka M, Li G, Zhu Y. Aberrant expression of collagen triple helix repeat containing1 in human solid cancers. Clin Cancer Res 2006;12(12):3716-22. (Pubitemid 44000252)
43. Yamamoto S, Nishimura O, Misaki K, Nishita M, Minami Y, Yonemura S, et al. Ctrc 1 selectively activates the planar cell polarity pathway of Wnt signaling by stabilizing the Wnt - receptor complex. Developmental cell. 2008;15:23-36. (Pubitemid 351895602)
44. Wang Y. Wnt/planar cell polarity signaling: a new paradigm for cancer therapy. MolCancerTher. 2009;8(8):2103-9.
45. Tang L, Dai DL, Su M, Martinka M, Li G, Zhou Y. Aberrant expression of collagen triple helix repeat containing 1 in human solid cancers. Clin Cancer Res. 2006;12:3716-22. (Pubitemid 44000252)